NFE2L2 and cancer: On the other hand, somatic mutations of the KEAP1 and NRF2 genes and KEAP1 hypermethylation in lung and other cancers result in the constitutive activation of NRF2 and the increased expression of cytoprotective genes which promote cancer cell survival, tumor promotion, and resistance against chemotherapy or radiotherapy [7–9].